Evidence map›Paper›PMID 40372496›Full record

ArticleHeart and vessels2025

Utility of convolutional neural network-enhanced electrocardiogram to diagnose and predict mitral regurgitation in patients with chronic atrial fibrillation.

Mayu Sakuma, Shinya Suzuki, Naomi Hirota, Jun Motogi, Takuya Umemoto, Hiroshi Nakai, Wataru Matsuzawa, Tsuneo Takayanagi, Akira Hyodo, Keiichi Satoh and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Heart and vessels, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Mayu SakumaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan. myhr_espoir@yahoo.co.jp.ORCID http://orcid.org/0009-0007-1118-0472
Shinya SuzukiDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.
Naomi HirotaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.
Jun MotogiNihon Kohden Corporation, Tokyo, Japan.
Takuya UmemotoNihon Kohden Corporation, Tokyo, Japan.
Hiroshi NakaiInformation System Division, The Cardiovascular Institute, Tokyo, Japan.
Wataru MatsuzawaNihon Kohden Corporation, Tokyo, Japan.
Tsuneo TakayanagiNihon Kohden Corporation, Tokyo, Japan.
Akira HyodoNihon Kohden Corporation, Tokyo, Japan.
Keiichi SatohNihon Kohden Corporation, Tokyo, Japan.
Takuto AritaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.
Naoharu YagiDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.
Mikio KishiDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.
Hiroaki SembaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.
Hiroto KanoDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.
Shunsuke MatsunoDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.
Yuko KatoDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.
Takayuki OtsukaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.
Junji YajimaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.
Yasuchika TakeishiDepartment of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan.
Tokuhisa UejimaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.
Yuji OikawaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.
Takeshi YamashitaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Funding

Grants-in-Aid for Scientific Research, Kakenhi 24K19071Japan Agency for Medical Research and Development JP17ek0210082
6 · The paper itself

Abstract

A convolutional neural network (CNN)-enhanced electrocardiogram (ECG) has been reported for detecting mitral regurgitation (MR). This tool may be particularly useful for identifying candidates for echocardiography in patients with chronic atrial fibrillation (AF) to detect atrial functional MR early. The data from a single-center, prospective cohort study (Shinken Database 2010-2017, n = 19,170) were combined with an ECG database. Initially, a CNN model was developed to detect MR (Grade ≥ 3) across the entire cohort using fivefold cross-validation. The model was refined using sublabels, including primary MR, MR with chronic AF and left atrial dilatation, and MR with left ventricular remodeling, to create an integrated neural network (INN) model. We then analyzed the relationship between MR diagnosed by the INN and the MR prevalence in chronic AF patients. In the CNN model, the AUCs of the ROC curve and PR curve in 0.836 (SD: 0.022) and 0.196 (SD: 0.036), which numerically increased to 0.848 (SD: 0.014) and 0.198 (SD: 0.031) in the INN model. The Grad-CAM analysis revealed that the CNN algorithm appears to highlight nonspecific ECG features, such as P-waves in the leads V1 to V2 (or f-wave in the lead V1) and R-wave amplitude or ST-T changes in precordial leads, which may explain the high false-positive rate in the model. When applying the model to CAF patients, although the sensitivity was around 0.9 at the threshold determined by the ROC curve, PPR and F1 score was relatively low. These metrics slightly improved when adjusting the threshold to that corresponding to a sensitivity of 0.8 and further improved by restricting the target population to those with BNP ≥ 100 pg/mL. The INN model improved MR detection performance compared to the initial CNN model, but the overall PPR remained suboptimal. High false-positive rates remained an issue, even in high-prevalence populations such as CAF patients or those with elevated BNP values.

Indexed as

Atrial FibrillationElectrocardiographyMitral Valve InsufficiencyNeural Networks, ComputerAdultAgedChronic DiseaseConvolutional Neural NetworksEchocardiographyFemaleHumansJapanMaleMiddle AgedPredictive Value of TestsProspective StudiesArtificial intelligenceElectrocardiographyMitral regurgitation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.